Rohit Aggarwal, Md

This study tested whether adding nintedanib (OFEV) to standard immunosuppressant therapy can improve symptoms in people with myositis-associated interstitial lung disease, a condition where lung tissue becomes scarred and stiff. 49 adults in the U.S. participated, receiving eithe…